Browsing by Subject "Drugs, Investigational"
Now showing items 1-4 of 4
-
Returns to R&D on new drug introductions in the 1980s.
(J Health Econ, 1994-12)This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ... -
The distribution of sales revenues from pharmaceutical innovation.
(Pharmacoeconomics, 2000)OBJECTIVE: This report updates our earlier work on the returns to pharmaceutical research and development (R&D) in the US (1980 to 1984), which showed that the returns distributions are highly skewed. It evaluates a more ... -
The price of innovation: new estimates of drug development costs.
(J Health Econ, 2003-03)The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ... -
The quantity and quality of worldwide new drug introductions, 1982-2003.
(Health Aff (Millwood), 2006-03)We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and ...